Edition:
United States

Navidea Biopharmaceuticals Inc (NAVB.A)

NAVB.A on American Stock Exchange

0.56USD
2:16pm EDT
Change (% chg)

$-0.02 (-2.86%)
Prev Close
$0.58
Open
$0.56
Day's High
$0.57
Day's Low
$0.55
Volume
20,657
Avg. Vol
118,163
52-wk High
$1.51
52-wk Low
$0.26

Latest Key Developments (Source: Significant Developments)

Cardinal Health reports 5.8 pct passive stake in Navidea Biopharma
Monday, 13 Mar 2017 04:03pm EDT 

Cardinal Health Inc :Cardinal Health, Inc reports 5.8 percent passive stake in navidea biopharmaceuticals inc as of March 3, 2017 - sec filing.  Full Article

Navidea Biopharmaceuticals says reaches settlement with CRG relating to loan agreement
Thursday, 23 Feb 2017 10:32am EST 

Navidea Biopharmaceuticals Inc : Navidea Biopharmaceuticals - On Feb 22, 2017, Co, CRG, and Cardinal Health 414 read into record a settlement in interpleader action pending in Ohio . Navidea Biopharmaceuticals Inc - Parties agreed that CRG will be paid $59 million - SEC filing . Navidea Biopharmaceuticals - Co, CRG agreed that the $2 million currently being held in escrow pursuant to court order in the Ohio case - SEC filing . Navidea Biopharmaceuticals Inc - Cardinal Health 414 will post a $7 million letter of credit in favor of CRG .Navidea Biopharmaceuticals - Co, CRG agreed $3 million currently being held in escrow pursuant to court order in Texas case to be released to co at closing of deal.  Full Article

Navidea enters into letter of intent with cardinal health for sale of Lymphoseek in North America
Tuesday, 6 Sep 2016 06:59am EDT 

Navidea Biopharmaceuticals Inc: Navidea Biopharmaceuticals enters into letter of intent with cardinal health for the sale of Lymphoseek® in North America . Total consideration to Navidea would be capped at $310 million. . Navidea retains rights to non-competitive diagnostic indications and all therapeutic applications .Navidea would receive $80 million at closing, with future consideration tied to annual sales of Lymphoseek, certain milestones.  Full Article

Navidea Biopharmaceuticals says files for non-timely 10-Q
Wednesday, 10 Aug 2016 03:46pm EDT 

Navidea Biopharmaceuticals Inc : Says files for non-timely 10-Q - SEC Filing . Says company is still in the process of gathering certain required documentation Source - http://bit.ly/2aMWOmN Further company coverage: [NAVB.A] ((Bangalore.newsroom@thomsonreuters.com;)).  Full Article

Navidea Biopharmaceuticals Q2 loss per share $0.04
Thursday, 4 Aug 2016 06:59am EDT 

Navidea Biopharmaceuticals Inc : Navidea reports second quarter 2016 financial results . Q2 revenue $5.4 million . Q2 loss per share $0.04 . Continuing to explore alternative financing arrangements in order to refinance crg debt ."believes that actions of CRG are a violation of loan agreement and, as a result, CRG is in breach of loan agreement".  Full Article

Navidea gets IRB nod for Lymphoseek rheumatoid arthritis trial protocol
Tuesday, 19 Jul 2016 06:59am EDT 

Navidea Biopharmaceuticals Inc : Navidea receives IRB approval for its Lymphoseek rheumatoid arthritis clinical trial protocol . Study will begin enrolling patients shortly .Navidea has received WIRB IRB approval to expand this study to other study sites at Navidea's discretion.  Full Article

Navidea Biopharma says continuing to explore alternative financing to refinance some debt
Thursday, 2 Jun 2016 05:55pm EDT 

Navidea Biopharmaceuticals Inc : Received letter dated May 31, 2016 from Capital Royalty Partners II L.P and Capital Royalty Partners II Parallel Fund A L.P. (CRG) . Company is continuing to explore alternative financing arrangements in order to refinance some debt - SEC filing . Company disputes amounts claimed to be due and believes that CRG does not have right to accelerate loan . "Believes that actions of CRG are violation of loan agreement and, as a result, CRG is in breach of loan agreement, not co" . Reiterates its firmly held position that alleged claims do not constitute events of default under loan agreement . "Company believes that its best course of action is to refinance CRG debt and pursue its claims for damages" . CRG declared all of co's obligations under loan agreement,all other loan documents to be immediately due and payable in amount of $56.1 million . Reiterates position that alleged claims do not constitute events of default under loan agreement ."Company is working on preparation of counterclaims which it expects to assert".  Full Article

Navidea says received unsolicited offer to refinance CRG loan facility
Monday, 23 May 2016 06:55am EDT 

Navidea Biopharmaceuticals Inc : Received an unsolicited offer to refinance entire existing CRG loan facility . Approach should allow co to refinance all of outstanding CRG debt . Institutional investor also indicated that they could have facility closed and funded within 120 days . Proposed facility has a similar interest rate and duration to existing facility, but does not have same restrictive maintenance covenants . "will continue ongoing dialogue with banks, continue to seek out every avenue available to streamline capital structure" .Navidea provides financing update.  Full Article

Navidea reports Q1 loss per share of $0.02
Tuesday, 17 May 2016 07:00am EDT 

Navidea Biopharmaceuticals Inc : Expects to begin grant-funded phase 1/2 evaluation of lymphoseek - iv in kaposi's sarcoma patients in second half of 2016 . Navidea reports first quarter 2016 financial results . Q1 loss per share $0.02 . Sees fy 2016 revenue $23 million to $25 million .Q1 revenue $4.7 million versus $2.1 million.  Full Article

Navidea Biopharmaceuticals says received demand for arbitration from CEO Ricardo Gonzalez
Friday, 13 May 2016 05:36pm EDT 

Navidea Biopharmaceuticals Inc : On May 12, received a demand for arbitration from Ricardo Gonzalez, company's chief executive officer - sec filing . Gonzalez claiming he was "terminated without cause", alternatively, claiming he resigned in accordance with section 4G of employment agreement . Notified Gonzalez his "failure to undertake responsibilities", otherwise work after being ordered to do so constituted effective resignation . Rejected resignation of Gonzalez pursuant to section 4G of his employment agreement . Notified Gonzalez that failure to return to work after expiration of cure period in employment agreement constituted cause for termination . On May 9, Brent Larson, chief financial officer, was approved for short term disability by company's insurance carrier . Brent Larson no longer acting as CFO .Jed Latkin, interim COO expected to function as principal executive officer, principal financial, accounting officer till replacements are hired.  Full Article

More From Around the Web